Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial

PURPOSE: The early identification of maximum tolerated dose (MTD) in phase I trial leads to faster progression to a phase II trial or an expansion cohort to confirm efficacy. METHODS: We propose a novel adaptive design for identifying MTD early to accelerate dose-finding trials. The early identifica...

Descripción completa

Detalles Bibliográficos
Autor principal: Kojima, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985324/
https://www.ncbi.nlm.nih.gov/pubmed/35382745
http://dx.doi.org/10.1186/s12874-022-01584-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985324/
https://www.ncbi.nlm.nih.gov/pubmed/35382745
http://dx.doi.org/10.1186/s12874-022-01584-y

Ejemplares similares